RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
RYET has entered the Malaysian healthcare market through an exclusive Cogni AI license agreement with BioNexus Gene Lab. The deal, which includes a license of up to 20 years and a reciprocal share exchange, entitles RYET to a 10% royalty on qualifying technology receipts and 560,000 BGLC shares as Malaysia accelerates public healthcare digitalization.
Why it matters — This expands RYET into Malaysia's digitalizing public healthcare sector and provides recurring royalty income plus equity in BioNexus Gene Lab.